CoChat

Multicentre randomized placebo‐controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis

Open access
Almasio, P. L., Floreani, A., Chiaramonte, M., Provenzano, G., Battezzati, P., Crosignani, A., Podda, M., Todros, L., Rosina, F., Saccoccio, G., Manenti, F., Ballardini, G., Bianchi, F. P., Scheuer, P. J., Davies, S. E., Craxì, A. · 2000 · Alimentary Pharmacology & Therapeutics
Cited by 53

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aim: To establish the efficacy of combination therapy with ursodeoxycholic acid (UDCA) and colchicine in patients with symptomatic primary biliary cirrhosis (PBC), defined by the presence of liver cirrhosis, pruritus or bilirubin exceeding 2 mg/mL. Methods: A total of 90 patients were randomly assigned to ursodeoxycholic acid 500 mg/daily plus placebo (UDCA group, n=44), or ursodeoxycholic acid at the same dosage plus colchicine, 1 mg/daily (UDCA/C group, n=46). The two groups were comparable for age, sex, stage of disease, severity of pruritus, bilirubin, and Mayo score. All patients underwent clinical, ultrasonographic, and biochemical examinations at entry and then every 6 months up to 3 years of follow‐up. Patients with cirrhosis underwent endoscopy every 12 months. In a sub‐group of patients without cirrhosis, who consented, liver biopsy was repeated at the end of the study. Results: The number of treatment failures (i.e. dead, orthotopic liver transplantation (OLT), complications of cirrhosis, doubling of bilirubin, untreatable pruritus) was 11 (25%) in the UDCA group and four (9%) in the UDCA/C group (P < 0.05). No significant differences were observed in terms of improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus. The Mayo score values increased less above the baseline values at 24 and 36 month‐intervals in the UDCA/C group than in the UDCA group. Histological evaluation at baseline and at the end of the study was available for 15 patients with pre‐cirrhotic stage. A significant reduction in histological grading score was observed in patients from the UDCA/C group, whereas no changes in these histological scores were observed in the UDCA group. Conclusions: The addition of colchicine to ursodeoxycholic acid in patients with symptomatic primary biliary cirrhosis results in a small but significant reduction of disease progress.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00869.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 53

Metadata

Authors
Almasio, P. L., Floreani, A., Chiaramonte, M., Provenzano, G., Battezzati, P., Crosignani, A., Podda, M., Todros, L., Rosina, F., Saccoccio, G., Manenti, F., Ballardini, G., Bianchi, F. P., Scheuer, P. J., Davies, S. E., & Craxì, A.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-12-27
Volume
14
Issue
12
Pages
1645-1652
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2081405405
Cited by
53
References
9
FWCI
2.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicentre randomized placebo‐controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00869.x
The paper
Almasio, P. L., Floreani, A., Chiaramonte, M., Provenzano, G., Battezzati, P., Crosignani, A., Podda, M., Todros, L., Rosina, F., Saccoccio, G., Manenti, F., Ballardini, G., Bianchi, F. P., Scheuer, P. J., Davies, S. E., & Craxì, A. (2000). Multicentre randomized placebo‐controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00869.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.